医学
彭布罗利珠单抗
头颈部鳞状细胞癌
肿瘤科
头颈部
内科学
放化疗
基底细胞
临床研究阶段
头颈部癌
放射治疗
化疗
癌症
总体生存率
外科
免疫疗法
作者
J.-P. Machiels,Lisa Francesca Licitra,Yungan Tao,C.-J. Yen,Danny Rischin,John N. Waldron,Barbara Ann Burtness,Vincent Grégoire,Sanjiv S. Agarwala,Jeffrey Thomas Yorio,Jean‐Pierre Delord,Sercan Aksoy,Sadakatsu Ikeda,Ruey‐Long Hong,Joy Yang Ge,Holly M. Brown,Behzad Bidadi,Lillian L. Siu
标识
DOI:10.1093/annonc/mdy287.078
摘要
Background: Preclinical data suggest improved tumor growth control and survival when radiation therapy (RT) is combined with a PD-1 inhibitor. Pembrolizumab is effective for treatment of recurrent/metastatic HNSCC, and initial results from a phase 1b study suggest that pembrolizumab plus chemoradiation therapy (CRT) is tolerable in patients with locally advanced (LA) HNSCC. KEYNOTE-412 (NCT03040999) is a phase 3, randomized, placebo-controlled, double-blind trial to determine efficacy and safety of pembrolizumab plus CRT and as maintenance therapy vs placebo plus CRT in LA-HNSCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI